Analysts Information
Somaiya, M. IanSr. Research AnalystIan Somaiya is a managing director and senior research analyst at Piper Jaffray covering the biotechnology industry. Prior to joining Piper Jaffray in 2010, Somaiya worked in equity research at Thomas Weisel Partners. Somaiya was recognized as "Best on the Street" by The Wall Street Journal in 2006 and 2007 for his biotechnology coverage. Formerly, Somaiya was a senior analyst at Morgan Stanley with responsibilities for small- and mid-capitalization biotechnology companies. He spent a year with The Carson Group in its healthcare consulting practice prior to making his transition to the sell-side at Prudential Securities. Somaiya received a bachelor of arts degree in biology/neuroscience from New York University. | Associates:Blaug, Sasha Kim, Do |
| Universe Coverage: Health Care: Biotechnology | |
| AFFY | Affymax, Inc. |
| ALXN | Alexion Pharmaceuticals, Inc. |
| AMGN | Amgen Inc. |
| AMLN | Amylin Pharmaceuticals, Inc. |
| RDEA | Ardea Biosciences |
| BIIB | Biogen Idec Inc. |
| BMRN | BioMarin Pharmaceutical Inc. |
| CELG | Celgene Corporation |
| GENZ | Genzyme Corporation |
| GILD | Gilead Sciences, Inc. |
| HGSI | Human Genome Sciences, Inc. |
| NBIX | Neurocrine Biosciences Inc. |
| RIGL | Rigel Pharmaceuticals |
| THRX | Theravance Inc. |
